Taysha Gene Therapies Inc
(NAS:TSHA)
$
1.93
0.05 (2.66%)
Market Cap: 395.54 Mil
Enterprise Value: 290.14 Mil
PE Ratio: 0
PB Ratio: 4.49
GF Score: 36/100 Taysha Gene Therapies Inc at JMP Securities Life Sciences Conference Transcript
Jun 16, 2022 / 05:00PM GMT
Release Date Price:
$2.87
(-4.65%)
Silvan Türkcan
JMP Securities LLC - Analyst
My name is Silvan Türkcan; I cover precision medicines here at JMP Securities. It's my pleasure to host Kamran Alam, CFO of Taysha; and Suyash Prasad, Chief Medical Officer of Taysha. Thank you very much for joining us today.
Kamran Alam
Taysha Gene Therapies, Inc. - CFO
Thanks very much. Appreciate it.
Suyash Prasad
Taysha Gene Therapies, Inc. - CMO & Head of Research and Development
Pleasure to be here.
Questions & Answers
Silvan Türkcan;Suyash Prasad
JMP Securities LLC - Analyst;Taysha Gene Therapies, Inc. - CMO
Thanks. So obviously, gene therapies have had a unique set of issues over the last, call it, 12 to 18 months apart from the general biotech market. Could you please tell us about what kind of company are you building in the gene therapy space to weather some of the challenges that other competitors may have had? And what's your focus, and how do you make it work?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot